Background {#Sec1}
==========

Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by a chronic inflammatory condition of the gastrointestinal tract. On a worldwide basis, CD has a prevalence of 0.5 % with an annual incidence of 12.7 per 100,000 person-years \[[@CR1]\]. The inflammation associated with CD can reach through all layers of the intestinal wall, causing complications such as strictures and fistula. The terminal ileum is the most prevalent site for inflammation and strictures, often requiring surgical ileocecal resection. Different immunosuppressive therapies are commonly applied, such as thiopurines, corticosteroids, and anti-tumor necrosis factor (aTNF) agents, all of which have variable success rates. Aside from complications within the gastrointestinal tract, CD occasionally manifests itself in an extra-intestinal fashion. Certain CD-associated symptoms appear to be gender-specific \[[@CR2]\], with female-specific symptoms including irregular menstruation \[[@CR3], [@CR4]\] as well as an increased risk of complications during pregnancy \[[@CR5]\].

Despite the extensive research performed on CD, the etiology is unknown. Numerous studies have sought to associate genetic changes to the pathogenesis of CD with genome-wide association studies (GWAS) finding many loci that are associated with pathways that have been well established in IBDs, such as pattern recognition signaling, cytokine production, and autophagy \[[@CR6], [@CR7]\]. However, only 20 % of the estimated heritability (30--50 %) of CD can be explained by common genetic variants \[[@CR6], [@CR8], [@CR9]\]. A growing body of literature suggests that additional factors such as diet \[[@CR10]\], the gut-microbiome \[[@CR11]\] and the epigenome \[[@CR12]--[@CR15]\] add to the development and progression of CD.

While the genome remains static for one organism over time and across different cell types, the epigenome can vary considerably. One of the well-described epigenetic modifications is cytosine methylation, which involves the attachment of a methyl group to a cytosine followed by a guanine (CpG site). Aberrant methylation patterns have been implicated in many complex disorders, such as cancers \[[@CR16]\], diabetes \[[@CR17]\], and juvenile stress \[[@CR18]\]. In this study, the aim was to explore how the methylome of peripheral blood is affected in female CD patients. To this end, the HumanMethylation450 BeadChip array (450k) was used to find differentially methylated positions (DMPs) and regions (DMRs) in DNA isolated from peripheral blood. We specifically looked at blood due to the relative ease and non-invasive nature in obtaining the samples. First, we sought to find differentially methylated loci through a hypothesis-free approach. Here, we specifically chose to assess the methylome of female CD patients to see whether CD manifests in the methylome of chromosome X, the results of which could help understand female-specific CD symptoms. Second, we aimed at replicating previously reported genes through a hypothesis-driven approach, whereby we assessed the methylation patterns of CD-associated genes retrieved from GWAS \[[@CR6], [@CR8], [@CR9]\] and epigenome-wide association studies (EWAS) \[[@CR12]--[@CR14], [@CR19], [@CR20]\].

Results {#Sec2}
=======

Quality control and exploratory data analysis {#Sec3}
---------------------------------------------

Samples were processed according to the flowchart in Fig. [1](#Fig1){ref-type="fig"}. Initial quality control using MethylAid \[[@CR21]\] indicated that three CD patients failed the bisulfite conversion, hybridization, and overall methylation threshold, resulting in their exclusion from downstream analyses. Subsequent principal component analysis did not reveal any discernable separation of the CD patients from the healthy controls (Fig. [2](#Fig2){ref-type="fig"}). Moreover, the first principal component explained only 12.5 % of the variance, suggesting that the DNA methylome does not differ considerably among samples (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a). As the DNA samples were obtained from peripheral blood, the concern existed that the heterogeneity of the blood cell composition confounded our data \[[@CR22], [@CR23]\]. We therefore estimated the cellular composition per sample using the algorithm described in Houseman et al. \[[@CR23]\] (Additional file [1](#MOESM1){ref-type="media"}: Figure S1b). When comparing CD versus healthy controls, a difference in blood cell composition was observed, which was nominally statistically significant at an α (*p* value threshold) of 0.05. However, after correcting for multiple testing using the Bonferroni method, the associations were almost statistically significant suggesting that CD is potentially associated with changes in the cellular composition. Calculating the Pearson correlation coefficient for the blood cell distribution with each principal component revealed a strong correlation of the blood cell distribution with the first principal component. This correlation was statistically significant for CD8T cells, CD4T cells, natural killer cells, and granulocytes after correcting for multiple testing using the Benjamini-Hochberg (BH) procedure (Additional file [1](#MOESM1){ref-type="media"}: Figure S1c). We surmised that additional biological confounders included age \[[@CR24]\] and the usage of aTNF medication at the time of phlebotomy. To prevent age from confounding our data, we had age-matched our cohort prior to sampling. Correlating age and aTNF usage with the principal components revealed no significant correlation (*R*^2^ \> 0.10), suggesting that neither affect the methylome significantly (Additional file [1](#MOESM1){ref-type="media"}: Figure S1d, e). To correct for the most prominent (hidden) biological confounders, such as the cellular composition, we performed factor analysis using the RUVfit function \[[@CR22], [@CR25]--[@CR27]\]. RUVfit is a wrapper function for the "remove unwanted variation" (RUV) methods \[[@CR25]--[@CR27]\]. While it would have been possible to include the estimated blood cell composition obtained from the Houseman algorithm as covariates in the linear model, as described in Guintivano et al. \[[@CR28]\] and Hannum et al. \[[@CR24]\], this method was discouraged in Montaño et al. \[[@CR29]\] and Jaffe and Irizarry \[[@CR22]\] as the estimated blood cell composition was found to yield biased results. Instead, Jaffe and Irizarry suggested the usage of RUV as a way for correcting for composition-based confounding \[[@CR22]\]. The advantage of RUV over other conventional methods is its ability to discover (hidden) biological confounders aside from blood cell composition. For more information about our implementation of the RUVfit function, see Section [5](#Sec18){ref-type="sec"}.Fig. 1Data analysis workflow. A brief overview of our data analysis pipelineFig. 2Exploratory data analysis. Plot of the first two principal components of the overall DNA methylation profiles reveal no discernable differentiation between CD patients (turquoise triangles) and healthy controls (red circles)

Differentially methylated positions in Crohn's disease patients {#Sec4}
---------------------------------------------------------------

After normalizing the data and correcting for confounders, we observed 4287 significant DMPs (BH-adjusted *p* \< 0.05) that were associated to 2715 unique genes. Of the 4287 significant DMPs, 949 were hypomethylated with the remaining 3338 being hypermethylated (Additional file [2](#MOESM2){ref-type="media"}: Table S1). The two most significant DMPs were found within the protein tyrosine phosphatase *PTPRN2* \[Ensembl: ENSG00000155093\] and the zinc-finger protein *BCL11A* \[Ensembl: ENSG00000119866\], which were moderately hypermethylated in CD patients versus healthy controls (see dot-boxplots on the right of Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3Differentially methylated positions. **a** *Left*: Volcano plot of the --log10 transformed BH-adjusted *p* on the Y-axis versus the mean effect size in methylation (beta) on the X-axis. DMPs are indicated in *green. Right*: Dot-boxplots of the two most significant DMPs: cg26639747 (*PTPRN2*) and cg27159979 (*BLC11A*). **b** Comparison of the probe distribution on the 450k versus the DMP distribution per chromosome where the *different colors* represent the different chromosomes. The *numbers* along the *barplot* represent the percentages of the 450k probes (*top*) or DMPs *(bottom*) per chromosome. Significantly different DMP distributions are indicated in *bold red* with the *asterisks* indicating the level of significance as found in Additional file [5](#MOESM5){ref-type="media"}: Table S3 (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001). **c** For each chromosome, the percentage hypo- and hypermethylated DMPs is indicated with *barplots* in *black* and *gray*, respectively

Differentially methylated position distribution analysis {#Sec5}
--------------------------------------------------------

The precise fashion through which methylation affects transcription remains unknown with the current dogma being that hypermethylated regions within the transcription start site (TSS) silence the respective gene \[[@CR30], [@CR31]\]. To this end, we investigated the DMP distribution per genetic feature. Here, we used a Fisher exact test to calculate whether the ratio of DMPs versus the total number of 450k probes per genetic feature was significantly different from a DMP distribution originating by chance. We observed a statistically significant difference in the DMP distribution for the transcription start sites (TSS1500 and TSS200), the gene body, the first exon, the 3′ untranslated region (3′UTR) and the intergenic region (Additional file [3](#MOESM3){ref-type="media"}: Figure S2a and Additional file [4](#MOESM4){ref-type="media"}: Table S2). Only the 5′UTR was not statistically significant, suggesting that the DMPs are not randomly distributed. Next, we sought to test whether the direction of methylation was significantly different for any of the genetic features using a second Fisher exact test. Here, we found no statistically significant differences in the distribution of hypo- and hypermethylated DMPs for any of the genetic features (Additional file [3](#MOESM3){ref-type="media"}: Figure S2b, c and Additional file [4](#MOESM4){ref-type="media"}: Table S2).

A similar approach was used to assess the DMP distribution per chromosome. Here, we found a significantly different DMP distribution for chromosomes 1, 19, and X (Fig. [3b](#Fig3){ref-type="fig"}). Furthermore, analysis of the hypo- and hypermethylated DMP distribution revealed that while the autosomal chromosomes contained more hypermethylated DMPs than hypomethylated DMPs, the inverse was true for chromosome X (Fig. [3c](#Fig3){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S3). As we had a female-only cohort, we investigated chromosome X in further detail. Analysis of the X-associated DMPs yielded 32 DMPs of the 10,246 probes on chromosome X (Additional file [11](#MOESM11){ref-type="media"}: Table S4). Analysis of the genes associated to the X-linked DMPs revealed an enrichment of only two genes: *MIR223* \[Ensembl: ENSG00000207939\] (Fig. [4a](#Fig4){ref-type="fig"}) and *PABPC5* \[Ensembl: ENSG00000174740\] (Fig. [4b](#Fig4){ref-type="fig"}), which were represented by two and four DMPs, respectively.Fig. 4Differentially methylated positions on chromosome X. Visualization of the methylation levels of **a** *MIR223* and **b** *PABPC5* ("450K") located on the chromosome X superposed onto the RefSeq genes ("RefSeq gene"). *Enlarged strip/boxplots* are provided for the significant CpGs, namely *MIR223*: cg06701191 and cg19127840, and *PABPC5*: cg16401529, cg04875162, cg09725213, and cg00608151

Differentially methylated regions in Crohn's disease patients {#Sec6}
-------------------------------------------------------------

Using the bumphunter function \[[@CR32]\], we found eight DMRs, which we associated to *HLA-J* \[Ensembl: ENSG00000204622\], *BOLA3* \[Ensembl: ENSG00000163170\], *TACSTD2* \[Ensembl: ENSG00000184292\], *APOBEC1* \[Ensembl: ENSG00000111701\], *MOV10L1* \[Ensembl: ENSG00000073146\], *OR2L13* \[Ensembl: ENSG00000196071\], *LINC00612* \[Ensembl: ENSG00000214851\], and *SHANK2* \[Ensembl: ENSG00000162105\] (Table [1](#Tab1){ref-type="table"}). While the individual CpGs comprising the DMRs were not significantly differentially methylated, the mean difference across the entire region was moderate but noticeable (Additional file [6](#MOESM6){ref-type="media"}: Figure S3).Table 1DMRs as predicted by the bumphunter function, containing four or more consecutive DMPsDMR location (hg19)Mean effect sizeArea DMRDMPsNearest genechr6: 29895175-29895260−0.1726.89E-014HLA-Jchr2: 74357527-743578720.1275.10E-014BOLA3chr1: 59043199-590432800.1214.83E-014TACSTD2chr12: 7781004-7781288−0.1184.72E-014APOBEC1chr22: 50528213-50528312−0.09923.97E-014MOV10L1chr1: 248100345-2481005850.09353.74E-014OR2L13chr12: 9217510-9217669−0.09183.67E-014LINC00612chr11: 70672841-706728780.09113.65E-014SHANK2

Pathway enrichment analysis of the differentially methylated positions {#Sec7}
----------------------------------------------------------------------

To understand the functional relevance of our reported DMPs, gene ontology (GO) enrichment analysis was performed. GO enrichment yielded 32 significantly enriched (BH-adjusted *p* \< 0.05) processes, with notable hits for immune response (GO:0006955 and GO:0002376) and leukocyte activation (GO:0045321) as well as neutrophil chemotaxis (GO:0030593) (Table [2](#Tab2){ref-type="table"}).Table 2Statistically significant gene ontology enrichment on our significant DMPsGOTerm*p* valueBH-adjusted *p* valueGO:0002376Immune system process1.58E-071.60E-03GO:0006955Immune response9.61E-081.60E-03GO:0007166Cell surface receptor signaling pathway7.25E-074.86E-03GO:0060326Cell chemotaxis9.63E-074.86E-03GO:0006909Phagocytosis3.92E-061.55E-02GO:0030593Neutrophil chemotaxis4.60E-061.55E-02GO:0098602Single organism cell adhesion5.62E-061.62E-02GO:0006952Defense response1.97E-052.79E-02GO:0048583Regulation of response to stimulus1.44E-052.79E-02GO:0016337Single organismal cell-cell adhesion2.07E-052.79E-02GO:0045321Leukocyte activation1.54E-052.79E-02GO:0050900Leukocyte migration1.84E-052.79E-02GO:0030595Leukocyte chemotaxis2.06E-052.79E-02GO:1990266Neutrophil migration1.84E-052.79E-02GO:0071621Granulocyte chemotaxis1.80E-052.79E-02GO:0071944Cell periphery2.28E-052.88E-02GO:0001775Cell activation2.66E-053.10E-02GO:0034109Homotypic cell-cell adhesion2.76E-053.10E-02GO:0016477Cell migration3.42E-053.63E-02GO:0006954Inflammatory response3.94E-053.76E-02GO:0007165Signal transduction4.36E-053.76E-02GO:0048870Cell motility4.61E-053.76E-02GO:0051674Localization of cell4.61E-053.76E-02GO:0070486Leukocyte aggregation4.21E-053.76E-02GO:0002696Positive regulation of leukocyte activation4.98E-053.76E-02GO:0071800Podosome assembly4.69E-053.76E-02GO:0009897External side of plasma membrane5.02E-053.76E-02GO:0007159Leukocyte cell-cell adhesion5.70E-054.11E-02GO:0098552Side of membrane6.54E-054.56E-02GO:0044700Single organism signaling7.07E-054.72E-02GO:0050867Positive regulation of cell activation7.25E-054.72E-02GO:0009611Response to wounding7.84E-054.95E-02

Overlap with previous studies {#Sec8}
-----------------------------

Next, we compared the genes associated to our DMPs with genes associated to CD and IBD from previous GWAS \[[@CR6], [@CR8], [@CR9]\] and EWAS \[[@CR12]--[@CR14], [@CR19], [@CR20]\] data. The GWAS-derived list contained 275 genes whereas the EWAS-derived list contained 4388 genes. When comparing the GWAS, the EWAS and our own data, we found 33 genes that were present in all three datasets. Analysis of the CpGs associated to the 33 overlapping genes yielded 136 statistically significant hypothesis-driven DMPs (BH-adjusted *p* \< 0.05) (Additional file [7](#MOESM7){ref-type="media"}: Table S5). Of the ten most significant hypothesis-driven DMPs, five DMPs were associated to *TNF* \[Ensembl: ENSG00000232810\] (Fig. [5c](#Fig5){ref-type="fig"}) and two were associated to *SP140* \[Ensembl: ENSG00000079263\] (Fig. [5b](#Fig5){ref-type="fig"}). Interestingly, while the hypothesis-driven DMPs found in *TNF* appear to occur consecutively, our previous DMR analysis did not yield any hits for *TNF*, which might be due to the limited mean difference observed across the *TNF*-associated DMPs. To validate our findings for *SP140* and *TNF*, we performed MiSeq amplicon sequencing and correlated the results with our findings obtained from the 450k data. The methylation levels obtained from the MiSeq sequencing were found to be concordant with the 450k results for SP140 (see MiSEQ track in Fig. [5b](#Fig5){ref-type="fig"}). Unfortunately, we were unable to obtain sufficient reads with the primers designed for our region of interest for TNF. We therefore sequenced downstream of our region of interest, which yielded adequate reads and revealed methylation levels similar to what was found using the 450k (see MiSEQ track in Fig. [5c](#Fig5){ref-type="fig"}). In addition to *SP140* and *TNF*, specific regions within *TNFSF4* \[Ensembl: ENSG00000117586\] (Additional file [8](#MOESM8){ref-type="media"}: Figure S4b), *IL10*/*IL19* \[Ensembl: ENSG00000136634\] (Additional file [8](#MOESM8){ref-type="media"}: Figure S4c), and *ORMDL3* \[Ensembl: ENSG00000172057\] (Additional file [8](#MOESM8){ref-type="media"}: Figure S4d) were also sequenced, as they had been associated with CD previously \[[@CR6]\]. Overall, the methylation levels obtained through MiSeq sequencing were found to be concordant with the methylation levels obtained from the 450k array (Additional file [8](#MOESM8){ref-type="media"}: Figure S4a), but the differences between CD patients and healthy controls were not statistically significant.Fig. 5Hypothesis-driven differentially methylated positions. **a** Venn diagram representing the overlap between CD-associated genes from our data (2715 genes), GWAS data (275 genes), and EWAS data (4388 genes). Genomic plots of the methylation levels of the DMPs obtained from the 450k ("450K") compared to the methylation levels obtained from MiSeq sequencing ("MiSEQ") superposed on known RefSeq genes ("RefSeq gene") for **b** *SP140* and **c** *TNF*. Note that the MiSeq sequencing of SP140 missed one CpG covered by the 450k, which was specifically removed due to low read count (\<100; see Section [5](#Sec18){ref-type="sec"} "[Illumina MiSeq Sequencing](#Sec27){ref-type="sec"}"). *Enlarged dot-boxplots* are provided for the significant CpGs associated to *TNF*: cg23384708, cg20477259, cg26736341, cg1360627, and cg17741993, and *SP140*: cg05564251 and cg04579254. Dot-boxplots of **d** cg16176675 (*TIFAB*) and **e** cg01476222 (*TRAF6*), as reported from McDermott et al.

In particular, we assessed the methylation levels of the top DMPs as reported by McDermott et al. due to the similarity in design and goals with our current study \[[@CR13]\]. While our results mostly correspond with respect to the direction of methylation, our reported effect sizes differ (Additional file [9](#MOESM9){ref-type="media"}: Table S6). Visualization of the DMPs found in *TIFAB* \[Ensembl: ENSG00000255833\] (cg16176675) and *TRAF6* \[Ensembl: ENSG00000175104\] (cg01476222), which represent the top DMP and the validated DMP reported by McDermott et al., displayed a minor difference that was not statistically significant in our data (Fig. [5d](#Fig5){ref-type="fig"}, [e](#Fig5){ref-type="fig"}). For certain DMPs, we appear to observe opposite effects. Analysis of the contentious DMPs reveals an association with UC in the dataset of McDermott et al. suggesting CD-specific methylation.

Discussion {#Sec9}
==========

Quality control and exploratory data analysis {#Sec10}
---------------------------------------------

In this study, we studied the methylation differences between female CD patients versus healthy controls in peripheral blood. To our knowledge, we are the first to perform methylation analysis in peripheral blood using a female-only cohort, which provided us with the opportunity to investigate CD-associated methylome manifestations on chromosome X. We used peripheral blood as our sample of interest, with the intention of discovering epigenetic loci that could be of use in the clinical setting. As peripheral blood is a heterogeneous population, our results were confounded by the change in blood cell distribution in the presence of CD. To correct for the blood cell distribution, we implemented the RUVfit function \[[@CR22], [@CR25]\].

Differentially methylated positions in Crohn's disease patients {#Sec11}
---------------------------------------------------------------

Our analysis yielded 4287 sites that displayed statistically significant differences in methylation for CD patients versus healthy controls. Despite finding many DMPs, the effect sizes were limited, which reflects the results obtained by Harris et al. \[[@CR12]\] and McDermott et al. \[[@CR13]\]. The two most significant DMPs were found in *PTPRN2* and *BCL11A*, with the former being associated to type 1 diabetes in mice \[[@CR33]--[@CR35]\] and the latter to type 2 diabetes in human males \[[@CR36]\]. Previous research showed that PTPRN2 in rats displays phosphatase activity towards inositol phospholipids \[[@CR37]\], whereas BCL11A in mice acts as a negative regulator of p53 \[[@CR38]\]. From the literature, it appears as though *PT2RN2* and *BCL11A* are involved in generic pathways suggesting that deregulation of generic pathways underlie complex disorders such as CD.

Differentially methylated position distribution analysis {#Sec12}
--------------------------------------------------------

Analysis of the distribution of DMPs across genetic features revealed that the DMPs are not randomly distributed. However, no particular enrichment of either the hyper- or hypomethylated DMPs was observed. A similar DMP distribution analysis for the chromosomes revealed significant differences in DMP distributions for chromosomes 1, 19, and X, where chromosome X displayed a significant depletion in DMPs versus the other chromosomes. The limited number of DMPs on chromosome X corroborates the overall nongender-specific nature and incidence of CD \[[@CR1]\]. Of the limited number of X-linked DMPs, we found an enrichment of DMPs associated to the microRNA *MIR-223* and *PABPC5*. MIR-223 plays an important role in promoting granulocyte differentiation \[[@CR39]\] whose deregulation is associated with various cancers \[[@CR40]--[@CR42]\] as well as endothelial cell apoptosis \[[@CR43]\], implicating a putative role in the formation of ulcers in CD patients. Additionally, *MIR-223* expression was found to be elevated in the inflamed ileum of CD patients \[[@CR44]\], with the expression of *MIR-223* being tightly regulated through histone acetylation and DNA methylation by the AML1/ETO fusion protein, making it an interesting target for future research \[[@CR45]\]. The available literature on *PABPC5* describes its discovery based on similarity towards poly(A) binding proteins, suggesting a role in transcriptional regulation. Similar to PTPRN2 and BCL11A, it appears as though PABPC5 is involved in a generic pathway. Nonetheless, the fact that four DMPs were associated to PABPC5 makes it an interesting candidate for future research on CD.

Differentially methylated regions in Crohn's disease patients {#Sec13}
-------------------------------------------------------------

In addition to DMPs, we found eight DMRs. One of the DMRs was located upstream of the major histocompatibility complex *HLA-J* (Additional file [6](#MOESM6){ref-type="media"}: Figure S3). HLA genes are involved in immunoregulation and have been implicated in the pathogenesis of CD previously \[[@CR6]\]. Another DMR was associated to *MOV10L1*, which has been described as an RNA helicase involved in piRNA processing \[[@CR46], [@CR47]\]. Using the ENCODE data in the UCSC Genome Browser, we observed that the MOV10L1-DMR associates to a region that contains transcription factor binding sites (TBFS) \[[@CR48]\] for two genes, namely *EGR1* \[Ensembl: ENSG00000120738\] and *ZBTB33* \[Ensembl: ENSG00000177485\]. EGR1 is involved in inflammation through its regulation of downstream targets such as TNF \[[@CR49], [@CR50]\]. Inflamed intestinal tissue was found to display increased levels of *EGR1* expression in CD patients \[[@CR51]\]. The ZBTB33 protein is a zinc-finger transcriptional regulator, which binds methylated CpG sites conferring transcriptional repression in an in vitro setting \[[@CR52]\]. Unlike *EGR1*, no studies have associated *ZBTB33* to IBD. While it is enticing for us to suggest a link between our DMRs and the transcription factor binding sites obtained from UCSC Genome Browser, no proper conclusions can be drawn given that our samples are not the same and that TFBS are often cell-type specific \[[@CR53]\]. Further research is necessary to elucidate a putative interplay between our MOV10L1-DMR and *EGR1*.

Pathway enrichment analysis of the differentially methylated positions {#Sec14}
----------------------------------------------------------------------

Our GO-enrichment analysis revealed that our DMPs were enriched in pathways involved in inflammation and cell activation. Comparable results were reported by McDermott et al. where differential methylation in peripheral blood mononuclear cells from IBD patients was associated to genes involved in immune response and T cell activation \[[@CR13]\]. Our data suggests that the DNA methylome is affected in genes that are involved in pathways associated to inflammation and immune response.

Overlap with previous studies {#Sec15}
-----------------------------

By comparing our results with previous CD studies, we managed to replicate 33 genes. We confirmed the methylation status of *TNF*, *SP140*, *TNFSF4*, *IL10*/*IL19*, and *ORMDL3* through MiSeq amplicon sequencing. Our results therefore suggest that deregulation of the previously mentioned genes could occur at an epigenetic and genetic level, thereby contributing to the observed inflammatory phenotype.

Limitations of the current study {#Sec16}
--------------------------------

It is important to realize that the results obtained in the present study cannot be used as biomarkers. The limited sample size and the minor effect sizes observed obscure the number of true positives and negatives due to the lack of power. Increasing the power could be achieved through a meta-analysis whereby various studies of similar in design are combined. While we have provided a brief comparison of our results with other studies of similar design, a systematic meta-analysis is necessary to ascertain the limited effect sizes observed. As such, our results merely provide CpGs that are found to be associated to CD in our cohort, which nonetheless provide a platform for future studies to elucidate the role of methylation in CD.

Conclusions {#Sec17}
===========

This study has shown that CD affects the DNA methylome of peripheral blood in female CD patients versus healthy controls, with the affected genes being enriched in inflammatory pathways. While we report differentially methylated loci in peripheral blood, the effect sizes are limited which was expected given the multifactorial nature of CD. By elucidating the methylome-associated changes in CD, we sought to gain a better understanding of the role of epigenetics in the pathogenesis of CD, thereby opening up new windows of opportunities for research in the diagnosis or treatment of CD.

Methods {#Sec18}
=======

Patient inclusion {#Sec19}
-----------------

Our CD samples consisted of 18 female CD patients with histologically confirmed intestinal CD (age range: 22 to 43) that visited the outpatient clinic at the Academic Medical Centre (AMC) IBD department in Amsterdam, the Netherlands. Of the 18 CD cases, only 15 remained after quality control using the *MethylAid* (version 1.4.0) package \[[@CR21]\]. The healthy control samples were obtained from 25 anonymous healthy women (age range: 21 to 43) from the biobank located at the AMC Department of Clinical Genetics, DNA Diagnostics laboratory. Healthy female controls were defined as patients that tested screen-negative for specific DNA-mutations as part of genetic family studies. The assembly of this cohort was approved by the medical ethics committee of the Academic Medical Hospital (METC 08/330 \# 09.17.0268), and written informed consent was obtained from both the CD patients and control subjects.

DNA isolation and bisulfite conversion {#Sec20}
--------------------------------------

Peripheral blood was drawn and stored in EDTA to prevent coagulation. Erythrocytes were lysed before proteins were aggregated out of the sample. Genomic DNA was extracted through ethanol precipitation, after which the DNA was dissolved in tris-ethylenediaminetetraacetic buffer (Tris-EDTA) and stored at 4 °C. Subsequent bisulfite conversion of the DNA was performed using the Zymo EZ DNA Methylation™ kit following the manufacturer's protocol.

Methylation analysis {#Sec21}
--------------------

Whole-genome DNA methylation profiles were quantified using the Illumina HumanMethylation450k BeadChip Array, which measures 485,577 CpG sites at ServiceXS in Leiden, the Netherlands. Prior to 450k analysis, quality control of converted DNA was performed by means of high-resolution melting analysis of the *H19* locus \[Ensembl: ENSG00000130600\] according to the diagnostics workflow as described by Alders et al. \[[@CR54]\].

Differentially methylated loci analysis {#Sec22}
---------------------------------------

The methylation data was imported into the R statistical programming environment (version 3.2.2) using the Bioconductor package *minfi* (version 1.16.0) \[[@CR55]\]. Initial quality control was performed using the *MethylAid* package, whereby the quality of each sample was assessed using the internal control probes located on the BeadChip array \[[@CR21]\]. Subsequently, probes were removed that were known to be promiscuous, located on the Y-chromosome, or associated with CpGs with known SNPs (minor allele frequency \>0). The remaining probes were normalized using the functional normalization method \[[@CR56]\], after which *M* values (*M* = log~2~(*M*/*U*)) were used for statistical analyses and β-values (*β* = *M*/(*M* + *U* + 100)) were used for the visualization of the methylation levels \[[@CR57]\]. DMPs were obtained through linear regression using the *limma*package \[[@CR58], [@CR59]\].

DMRs were obtained using the DMR-finding function in *minfi* called bumphunter \[[@CR32], [@CR55]\]. In brief, bumphunter searches for DMRs by looking for CpGs with a mean difference above a certain threshold. We set the inclusion threshold to 0.08. To remove single CpGs that exceeded the inclusion threshold from our DMRs, we filtered for at least four consecutive CpGs to minimize the probability of randomly obtaining consecutive CpGs whose mean effect size are above 0.08 by chance. See Fig. [1](#Fig1){ref-type="fig"} for a brief summary of our workflow.

Batch effect correction using factor analysis {#Sec23}
---------------------------------------------

We accounted for technical batch effects using the functional normalization method, which estimates technical variation through the internal technical control probes located on the 450k array \[[@CR56]\]. Unlike technical batch effects, the technical control probes on the 450k array are unaffected by biological confounders. Finding and correcting for biological confounders was done through factor analysis, using the R function RUVfit found within the *missMethyl* package (version 1.4.0) \[[@CR60]\]. RUVfit implements the RUV ("remove unwanted variation") functions where negative control probes are used to estimate the effects of unwanted variation \[[@CR26], [@CR27]\]. Negative control probes are CpGs that are unaffected by the factor of interest but are affected by the batch effect. Due to the fact that we did not know a priori which CpGs were not differentially methylated, we followed the guidelines posted in the vignette of the *missMethyl* package \[[@CR25]\]. In short, a linear regression was performed on the CD status against the uncorrected *M* values yielding statistically non-significant CpGs (BH-adjusted *p* \> 0.5). Such statistically non-significant CpGs were deemed unassociated with CD and were therefore used as negative control probes. We then called the RUVfit function using the RUV-inverse ("RUVinv") function from the *ruv* package (version 0.9.6) to estimate and correct for batch effects \[[@CR25]--[@CR27]\].

Differentially methylated position distribution analysis {#Sec24}
--------------------------------------------------------

The DMPs were stratified per genetic feature/chromosome and compared to the total number of 450k probes associated to the respective genetic feature/chromosome. A Fisher exact test of independence was then used to calculate the probability that the number of DMPs found for a specific genetic feature/chromosome was significantly different from the expected number of DMPs. A second Fisher exact test was then performed on the number of hypermethylated DMPs versus the hypomethylated DMPs to assess whether the distribution was significantly different in any genetic feature/chromosome. Our threshold for statistical significance was set to a Bonferroni-adjusted α of 0.05.

Gene ontology enrichment analysis {#Sec25}
---------------------------------

Gene ontology (GO) enrichment analysis was performed on the DMPs using the gometh function from the R *missMethyl* package \[[@CR60]\]. The gometh function corrects for the number of probes per pathway thereby giving a balanced overview of the enriched pathways.

Hypothesis-driven analysis {#Sec26}
--------------------------

To compare our data with previous GWAS and EWAS data, we generated lists of unique genes acquired from GWAS and EWAS. The GWAS genes consisted of genes associated to the significant loci reported in the summary statistics obtained from Franke et al. \[[@CR9]\], Jostins et al. \[[@CR6]\], and Liu et al. \[[@CR8]\] whereas the EWAS genes consisted of genes associated to significant loci reported in the summary statistics obtained from Lin et al. \[[@CR20]\], Nimmo et al. \[[@CR14]\], Karatzas et al. \[[@CR19]\], and McDermott et al. \[[@CR13]\]. We then compared and looked for the genes that were present in all three gene lists and extracted the CpGs associated to these genes from our own data after which we adjusted for multiple testing accordingly.

Illumina MiSeq sequencing {#Sec27}
-------------------------

Technical validation of several promising 450k CpG sites was performed through targeted amplicon sequence analysis using the Illumina MiSeq platform. Primers were designed with a bisulfite-converted reference sequence, human genome build 19 (hg19), using Primer3 \[[@CR61], [@CR62]\]. Primer information is described in Additional file [10](#MOESM10){ref-type="media"}: Table S7. Amplicons were amplified through PCR and pooled per subject after which non-specific products were removed using the Agencourt AMPure PCR purification kit (Beckman Coulter). Pooled amplicons were elongated using TruSEQ indices and adapter sequences after which they were purified. Quality control of the amplicon length within the pools was performed using Agilent 2100 Bioanalyzer. DNA concentration was measured using Qubit 2.0 Fluorometer (ThermoFisher) and equalized to equimolar concentrations for all subject pools. MiSeq amplicon sequencing was then performed according to the standard protocol (Additional file [11](#MOESM11){ref-type="media"}: Table S4). Raw sequence data was mapped, aligned, and analyzed using GATK \[[@CR63], [@CR64]\], BWA, and Integrative Genomics viewer (version 2.3.57) \[[@CR65]\], respectively, against the bisulfite-converted hg19. A minimum of 100 reads per patient amplicon was deemed successful. While we were capable of correcting for (hidden) technical and biological confounders during the 450k methylation analysis, we were unable to correct for confounding factors during the MiSeq amplicon sequencing experiment.

Visualization of the differentially methylated loci {#Sec28}
---------------------------------------------------

Individual CpGs were visualized as a strip/boxplot using the *ggplot2* package (version 1.0.1) \[[@CR66]\]. Regions of CpGs as well as the CpG islands, the histone 3 single- and triple methylation, the DNase I hypersensitivity sites and the transcription factor-binding sites were retrieved from the UCSC Genome Browser and visualized using the *Gviz* package (version 1.14.0) \[[@CR67]\].

Abbreviations {#Sec29}
=============

450k, Illumina HumanMethylation450 BeadChip array; BH, Benjamini-Hochberg; CD, Crohn's disease; DMP, differentially methylated position; DMR, differentially methylated region; EWAS, epigenome-wide association study; GO, gene ontology; GWAS, genome-wide association study; IBD, inflammatory bowel disease; RUV, remove unwanted variation; TFBS, transcription factor binding sites; UC, ulcerative colitis

Additional files {#Sec30}
================

Additional file 1: Figure S1.Exploratory data analysis of putative biological confounders. a) Variance explained per principal component based on our 450k data (turquoise triangles) versus randomly generated data (red circles). b) Dot-boxplot of the cellular composition as estimated by the Houseman algorithm \[[@CR22], [@CR23]\]. c) Pearson correlation coefficient (R^2^) of each blood cell proportion with the principal components. The statistically significant correlations are indicated in turquoise, whereas statistically non-significant associations are indicated in red. Similar correlations were calculated for d) age and e) anti-TNF usage. (PDF 119 kb)Additional file 2: Table S1.Annotated data for the DMPs passing BH correction for the hypothesis-free approach. The location data: Illumina probe ID, chromosome, position, strand, UCSC gene symbol, UCSC genetic feature and regulatory feature, are shown along with the methylation statistics: mean beta difference, the *p* values and the BH-adjusted *p. (XLSX 403 kb)*Additional file 3: Figure S2.DMP-distribution per genetic feature and per chromosome. a) Comparison of the probe distribution on the 450k versus the DMP distribution per genetic feature where the different colors represent the different genetic features. The numbers along the barplot represent the percentages of the 450k probes (top) or DMPs (bottom) per genetic feature. Significantly different DMP-distributions are indicated in bold red with the asterisks indicating the level of significance as found in Additional file [5](#MOESM5){ref-type="media"}: Table S3 (\*: p \< 0.05, \*\*: p \< 0.01, \*\*\*: p \< 0.001, \*\*\*\*:p \< 0.0001). b) For each genetic feature the percentage hypo- and hypermethylated DMPs is indicated with barplots in black and gray respectively. (PDF 54 kb)Additional file 4: Table S2.DMP-distribution statistics per genetic feature. Results are ordered by the first Fisher test (left three columns), which tests for differences in DMP-distribution per genetic feature, and the second Fisher test (right three columns), which tests for differences in the distribution of the hypo-/hypermethylated DMPs. Statistics provided are the odds ratios with the 95 % confidence intervals ("OR (CI-95)"), the *p* values and the Bonferroni-adjusted *p* values. (DOCX 53 kb)Additional file 5: Table S3.DMP-distribution statistics per chromosome. Results are ordered by the first Fisher test (left three columns), which tests for differences in DMP-distribution per chromosome, and the second Fisher test (right three columns), which tests for differences in the distribution of the hypo-/hypermethylated DMPs. Statistics provided are the odds ratios with the 95 % confidence intervals ("OR (CI-95)"), the *p* values and the Bonferroni-adjusted *p* values. (DOCX 98 kb)Additional file 6: Figure S3.Differentially methylated regions. Plots of the methylation levels of the DMRs nearest to: a) *HLA-J*, b) *MOV10L1*, c) *LINC00612*, c) *SHANK2*, d) *APOBEC1*, e) *OR2L13* and f) *TACSTD2* from the 450k ("450K") superposed onto the RefSeq gene ("RefSeq gene"), the CpG island ("CGI") and the transcription factor binding sites ("TFBS"), as retrieved from the UCSC Genome Browser. The red transparent rectangle indicates the DMR as reported by bumphunter. (PDF 420 kb)Additional file 7: Table S5.Annotated data for the DMPs passing BH-correction for the hypothesis-driven approach. The location data: Illumina probe ID, chromosome, position, strand, UCSC gene symbol, UCSC genetic feature and regulatory feature, are shown alongside the methylation statistics: mean difference in beta, the *p* values and the BH-adjusted *p* values calculated for the hypothesis-free approach and the hypothesis-driven approach*. (XLSX 26 kb)*Additional file 8: Figure S4.MiSeq validation. a) Correlation of the methylation levels obtained from 450k and MiSeq. Each color represents the gene associated to the plotted CpG. Visualization of the methylation levels in beta of the DMPs obtained from the 450k ("450K") compared to the methylation levels obtained from MiSeq sequencing ("MiSEQ") superposed onto the RefSeq gene ("RefSeq gene") for b) *TNFSF4*, c) *IL10*/*IL19*, and d) *ORMDL3*. (PDF 146 kb)Additional file 9: Table S6.Comparison of the top DMPs reported by McDermott et al. with our own data. The location data: Illumina probe ID, chromosome, position, and associated gene are shown alongside the effect size per study. CpGs where opposite effects were found are indicated in bold. (DOCX 15 kb)Additional file 10: Table S7.MiSeq primers. The primer data used for MiSeq amplicon sequencing is shown alongside the included 450k probes. (DOCX 16 kb)Additional file 11: Table S4.DMPs on chromosome X. The location data: Illumina probe ID, chromosome, position, strand, UCSC gene symbol, UCSC genetic feature and regulatory feature, are shown alongside the methylation statistics: mean difference in beta, the *p* values and the BH-adjusted *p* values*.* DMPs associated to either *PABPC5* or *MIR223* are indicated in bold. (XLSX 12 kb)
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